Analytical platform for non-invasive diagnosis of LIVEr disease

Informations projet

ALIVE

N° de convention de subvention: 101111215

DOI

10.3030/101111215

Projet clôturé

Date de signature de la CE 2 Mars 2023

Date de début 1 Avril 2023

Date de fin 31 Mars 2025

Financé au titre de

• Marie Skłodowska-Curie Actions (MSCA)

Coût total

Aucune donnée

Contribution de l’UE

€ 187 624,32

Coordonné par

EXIT071 BV
Netherlands

Periodic Reporting for period 1 - ALIVE (Analytical platform for non-invasive diagnosis of LIVEr disease)

Période du rapport: 2023-04-01 au 2025-03-31

Résumé du contexte et des objectifs généraux du projet

The ALIVE project addressed the urgent need for more efficient, selective, and scalable methods for the separation and analysis of extracellular vesicles (EVs)-nanoscale carriers of biomolecules involved in cell-to-cell communication and promising biomarkers for disease diagnostics. Traditional techniques struggle to separate EVs from similar particles such as lipoproteins, particularly in clinical samples like blood plasma. ALIVE proposed an innovative electrophoretic strategy-depletion-zone isotachophoresis (dzITP), to fractionate EV subpopulations based on their electrophoretic mobility. Set against the backdrop of a growing demand for liquid biopsy tools, precision diagnostics, and affordable healthcare, the project aimed to develop a miniaturized, reusable chip platform capable of performing high-resolution EV separation. It combined electrokinetic technologies with mass spectrometry to enable lipidomic fingerprinting of EVs, offering new possibilities for disease biomarker discovery, particularly in liver-related disorders such as NAFLD. Through a series of proof-of-concept experiments, ALIVE demonstrated the capability of dzITP to separate EVs from lilpoproteins, protein and dye residues, as well as among EV subtypes. The integration of precise fraction retrieval methods, including electroosmotic flow control and segmented flow, opened avenues for downstream lipidomic profiling. The long-term goal is to translate this technology into a robust, scalable, and cost-effective diagnostic platform with direct applications in precision medicine and clinical research.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

This project contributed to the next generation of innovative methods for the separation and enrichment of extracellular vesicles. An improved method for electrokinetic separation was developed and published and patented. An improved microfluidic chips format was produced and tested.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

ALIVE introduced further investigated dzITP as a novel method for electrophoretic fractionation of EVs. Unlike traditional approaches, this method exploits ion-depleted zones to selectively focus analytes, achieving superior resolution of EV subtypes from co-isolated contaminants. The project demonstrated for the first time the compatibility of this approach with downstream lipidomic profiling using MS.

Andrea working with microchip

Public engagement event